Physicians' Academy for Cardiovascular Education

Results of ODYSSEY OUTCOMES and FOURIER trials complement each other

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USA

Messages from the ODYSSEY OUTCOMES trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Prof. Kausik Ray, Imperial College Londen, UK

Reversal agent for FXa inhibitors is effective and safe in interim analysis of ANNEXA-4 trial

3' education - Mar. 11, 2018 - Prof. Stuart Connolly, Hamilton, ON, Canada

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Ticagrelor non-inferior to clopidogrel for bleedings in post-STEMI patients

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, USA - Otavio Berwanger - São Paulo, Brasil

Pharmacist intervention in black barbershop beats usual care at lowering BP

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

No evidence that anti-inflammatory treatment prevents progression to T2DM in CANTOS trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Brendan Everett, MD - Boston, MA, USA

A threefold role of cardiologists as advocates for better cardiology care

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, VS - Mary Norine Walsh, MD - Indianapolis, IN, USA

Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA

Giving NOAC treatment at myocardial injury after non-cardiac surgery lowers major vascular complications

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, USA - P.J. Devereaux - Hamilton, ON, Canada

Total mortality, but not sudden cardiac death, lower by wearable cardioverter-defibrillator in the immediate post-MI period with low EF

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL. USA - Jeffrey Olgin (San Francisco, CA, USA

Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL. USA - Prof. Wouter Jukema - LUMC, The Netherlands

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg, Paris, France

Results of ODYSSEY OUTCOMES and FOURIER trials complement each other

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USA
Steven Nissen compares ODYSSEY OUTCOMES with FOURIER and concludes that the results of these studies in two different patient populations reinforce our understanding of the benefit of reducing LDL-c levels in patients with moderate LDL-c levels.

ACC 2018 Steven Nissen compares ODYSSEY OUTCOMES with FOURIER and concludes that the results of these 2 studies in 2 different patient populations reinforce our understanding of the benefit of reducing LDL-c levels in patients with moderate LDL-c levels.

Messages from the ODYSSEY OUTCOMES trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Prof. Kausik Ray, Imperial College Londen, UK
Prof. Ray considers current insights on the class of PCSK9 inhibiting monoclonal antibodies, and he looks ahead at another PCSK9 inhibiting agent.

ACC 2018 Prof. Ray considers current insights on the class of PCSK9 inhibiting monoclonal antibodies, and he looks ahead at another PCSK9 inhibiting agent.

Reversal agent for FXa inhibitors is effective and safe in interim analysis of ANNEXA-4 trial

3' education - Mar. 11, 2018 - Prof. Stuart Connolly, Hamilton, ON, Canada
Prof. Connolly summarizes the results of the interim analysis of the ANNEXA-4 trial: andexanet was effective in the reversal of the effect of FXa inhibitors and reversed FXa-associated bleedings in patients with acute major bleedings.

ACC 2018 Prof. Connolly summarizes the results of the interim analysis of the ANNEXA-4 trial: andexanet was effective in the reversal of the effect of FXa inhibitors and reversed FXa-associated bleedings in patients with acute major bleedings.

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil
Results of the SECURE-PCI trial showed a 28% decrease of MACE in patients treated with avorstatin compared to placebo before PCI intervention after ACS.

ACC 2018 Results of the SECURE-PCI trial showed a 28% decrease of MACE in patients treated with avorstatin compared to placebo before PCI intervention after ACS.

Ticagrelor non-inferior to clopidogrel for bleedings in post-STEMI patients

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, USA - Otavio Berwanger - São Paulo, Brasil
In patients post-STEMI, treatment with ticagrelor resulted in similar rate of TIMI-bleedings as clopidogrel after 30 days in the TREAT trial.

ACC 2018 In patients post-STEMI, treatment with ticagrelor resulted in similar rate of TIMI-bleedings as clopidogrel after 30 days in the TREAT trial.

CV benefit of PCSK9 inhibitor is consistent regardless of inflammation level

Literature - Mar. 13, 2018 - Bohula EA et al. - Circulation 2018
A prespecified FOURIER-analysis showed that evolocumab decreases CV events across hsCRP strata, with greater absolute risk reductions in patients with higher baseline hsCRP.

ACC 2018 A prespecified FOURIER-analysis showed that evolocumab decreases CV events across hsCRP strata, with greater absolute risk reductions in patients with higher baseline hsCRP.

Pharmacist intervention in black barbershop beats usual care at lowering BP

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA
Barbershops and pharmacists worked together to improve high BP in non-hispanic black men in Los Angeles County, a group with particularly high rates of uncontrolled hypertension. In a randomized design, a pharmacist intervention led to 27 mmHg drop over 6 months, vs. 9 mmHg in controls.

ACC 2018 Black barbershops and pharmacists worked together to improve high BP in non-hispanic black men. In a randomized design, a pharmacist intervention led to 27 mmHg drop in SBP over 6 months, vs. 9 mmHg in controls.

Reversal agent for FXa inhibitors safely reverses FXa inhibitor-associated major bleeding

Presented at ACC.18 by Stuart Connolly (Hamilton, ON, Canada)

News - Mar. 13, 2018

ACC 2018 In an interim analysis of the ANNEXA-4 study, andexanet rapidly reversed anti-FXa activity with an acceptable rate of adverse events in patients on FXa inhibitors with major bleeding.

No evidence that anti-inflammatory treatment prevents progression to T2DM in CANTOS trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Brendan Everett, MD - Boston, MA, USA
Due to the observed link between inflammation and aberrant insulin regulation, a key secondary outcomes of the CANTOS trial was new onset T2DM in patients with prediabetes at baseline.

ACC 2018 Due to the observed link between inflammation and aberrant insulin regulation, a key secondary outcomes of the CANTOS trial was new onset T2DM in patients with prediabetes at baseline.

A threefold role of cardiologists as advocates for better cardiology care

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, VS - Mary Norine Walsh, MD - Indianapolis, IN, USA
Mary Norine Walsh is the president of the ACC. She opened the congress by talking about the need for cardiologists to act as advocates, for quality, for each other, for patients, to create a better healthcare system.

ACC 2018 Mary Norine Walsh is the president of the ACC. She opened the congress by talking about the need for cardiologists to act as advocates, for quality, for each other, for patients, to create a better healthcare system.

Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA
A new analysis of the CANTOS trial showed that IL-1β inhibition with canakinumab in patients with stage 3 kidney disease did not slow progression to renal failure, but did beneficially alter outcomes in these very high risk patients.

ACC 2018 A new analysis of the CANTOS trial showed that IL-1β inhibition in patients with stage 3 kidney disease did not slow progression to renal failure, but did beneficially alter outcomes in these very high risk patients.

Giving NOAC treatment at myocardial injury after non-cardiac surgery lowers major vascular complications

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, USA - P.J. Devereaux - Hamilton, ON, Canada
The MANAGE trial studied the effect of the NOAC dabigatran in patients with myocardial injury after non-cardiac surgery. After a mean of 16 months follow-up, a relative risk reduction of 28% in major vascular complications was seen.

ACC 2018 The MANAGE trial studied the effect of dabigatran in patients with myocardial injury after non-cardiac surgery. After a mean of 16 months follow-up, a relative risk reduction of 28% in major vascular complications was seen.

ACC.18